Latest Placebo-controlled study Stories
TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd.
-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic
Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with
- Study Meets Primary and Both Key Secondary Endpoints - BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc.
RE-BODY® Launches RE-BODY Fruit & Flower Slimming Formula™ with Meratrim® Gainesville, Fla (PRWEB) February 13, 2014 RE-BODY®, a
Achieve is conducting a placebo-controlled, multicenter study to evaluate the blood pressure reduction with ambulatory blood pressure monitoring (ABPM), safety, and tolerability of a new drug
Natreon, Inc, and NutraGenesis, LLC are pleased to announce a new study published on Sensoril® demonstrates Sensoril’s ability to significantly improve cognitive and psychomotor performance.
OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc.
Plans to submit end of phase II meeting request to FDA SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).